Cat. No.: HY-150699 CAS No.: 1459695-66-9 Molecular Formula:  $C_{18}H_{10}BrF_{5}N_{2}O_{3}$ 

Molecular Weight: 477.18 Bacterial Target: Pathway: Anti-infection

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

## NH<sub>2</sub>

## **BIOLOGICAL ACTIVITY**

Description	TXA6101 is a bacterial protein FtsZ (filamentous temperature-sensitive protein Z) inhibitor that inhibits bacterial division. TXA6101 has antimicrobial activity against MRSA isolates expressing either the G193D or G196S mutant FtsZ with the MIC value of 1 $\mu$ g/mL, retains significant activity against the TXA707-resistant FtsZ mutant. TXA6101 can be used as a potential method against Gram-negative bacterial infections <sup>[1][2]</sup> .
In Vitro	TXA6101 has antibacterial activity against MRSA with the MIC value of 0.125 $\mu$ g/mL while TXA707 with the MIC value of 1 $\mu$ g/mL <sup>[2]</sup> . TXY6129 inhibits the polymerization of Escherichia coli FtsZ in a concentration-dependent manner and induces morphological changes in Escherichia coli and Klebsiella pneumoniae <sup>[3]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## **REFERENCES**

[1]. Andrea Casiraghi, et al. Targeting Bacterial Cell Division: A Binding Site-Centered Approach to the Most Promising Inhibitors of the Essential Protein FtsZ. Antibiotics (Basel). 2020 Feb 7;9(2):69.

[2]. Junso Fujita, et al. Structural Flexibility of an Inhibitor Overcomes Drug Resistance Mutations in Staphylococcus aureus FtsZ. ACS Chem Biol. 2017 Jul 21;12(7):1947-1955.

[3]. Jesus D Rosado-Lugo, et al. Evaluation of 2,6-difluoro-3-(oxazol-2-ylmethoxy) benzamide chemotypes as Gram-negative FtsZ inhibitors. J Antibiot (Tokyo). 2022 Jul;75(7):385-395.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA